Medicine and Dentistry
Patient
100%
Radiation Therapy
55%
Therapeutic Procedure
46%
Follicular Lymphoma
42%
Niraparib
29%
Computed Tomography
29%
Bone Density
26%
Follow up
25%
Computer Assisted Tomography
24%
Positron Emission Tomography
24%
Bevacizumab
23%
Recurrent Disease
20%
Overall Survival
19%
Platinum
18%
Diseases
18%
Diffuse Large B-Cell Lymphoma
16%
Fluorodeoxyglucose F 18
16%
Hazard Ratio
15%
Venous Thromboembolism
14%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
13%
Lymphoma
13%
Recurrent Ovarian Cancer
12%
Retrospective Study
9%
Age
9%
Malignant Neoplasm
9%
Analysis
9%
Relapse
9%
Inpatient
9%
Radiation Oncology
9%
Progression Free Survival
8%
Kaplan Meier Method
8%
Cancer Types
7%
Positron Emission Tomography-Computed Tomography
6%
Systemic Therapy
6%
Survival
6%
Biopsy
6%
Pharmacology, Toxicology and Pharmaceutical Science
Follicular Lymphoma
42%
Venous Thromboembolism
32%
Bevacizumab
23%
Recurrent Disease
20%
Overall Survival
19%
Platinum
18%
Diseases
18%
Fluorodeoxyglucose F 18
16%
Lymphoma
13%
Malignant Neoplasm
9%
Relapse
9%
Death
9%
Progression Free Survival
8%
Survival
6%
Radiation
6%
Vein Thrombosis
5%
Cohort Study
5%
Nursing and Health Professions
Niraparib
29%
Patient
29%
Bevacizumab
23%
Platinum
18%
Chemotherapy
15%
Venous Thromboembolism
14%
Malignant Neoplasm
9%
Confidence Interval
9%
Death
9%
Progression Free Survival
8%
Woman
8%
